Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces completion of enrollment in three Phase III trials of Saroglitazar Magnesium in NASH

Posted On: 2019-07-18 11:58:14

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has completed enrollment in EVIDENCES 11, EVIDENCES 111 and EVIDENCES V Phase3 clinical trials of Saroglitazar Mg for treating Non-Alcoholic SteatoHepatitis(NASH). Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico.

Speaking on the development Mr. Pankaj R. Patel, Chairman, Zydus group said, "We are excited about the progress that Saroglitazar Mg has been making in the NASH trials. It is currently being evaluated in over 23 different controlled clinical trials, involving over 3,800 patients. NASH is an area of unmet healthcare need and we are committed to develop this therapy for millions of patients suffering from this deadly disease.

EVIDENCES II is a Phase3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. The primary endpoint will be evaluated by histological improvementof NASH using liver biopsy at the end of 52 weeks.

EVIDENCES III is the prospective, multicenter, randomized, double-blind study of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic Fatty Liver Disease(NAFLD). This trial will measure the change in liver fat content as measuredby non-invasive magnetic resonance imaging (MRI) at week 24. Several other secondary endpoints including Liver stiffness as measured by transient elastography / FibroScan® and Serum alanine aminotransferase (ALT) level will also be evaluated.

EVIDENCES V will evaluate the NASH patients over a period of 18 months, measure the change in the liver fat content by magnetic resonance imaging-derived proton density-fat fraction (MRIPDFF) at Week 24 and evaluatethe liver biopsy driven endpoints of Saroglitazar 4 mg from baseline to Week 76.

Saroglitazar Magnesium was launched in India during September 2013, for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type-2 diabetes not controlled by statins. Saroglitazar Mg has demonstrated beneficial effects in NASH animal models. Saroglitazar Mg favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis in NASH models. Saroglitazar Mg has previously demonstrated improvelnent in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in PhaseII clinical trials.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.240.25 as compared to the previous close of Rs. 245.2. The total number of shares traded during the day was 88176 in over 1092 trades.

The stock hit an intraday high of Rs. 247 and intraday low of 238.6. The net turnover during the day was Rs. 21371852.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Wipro collaborates with FEBRABAN to develop noomis™

Clarification on the moneycontrol.com article "Thomas Cook India under MCA scanner over 'suspicious' transaction"

ICRA credit rating for the Fixed Deposit Programme of Axis Bank Limited

L&T triumphs Project of the Year award at the 11th Project Management Institute (PMI) India Awards 2019

Zensar expands operations in Cape Town, South Africa

Bajaj Finance Limited board to consider Q1, H1 results on Oct 22, 2019

Indo National Ltd to provide Rs. 3.50 crore corporate guarantee to Kineco Ltd

Manappuram Finance Ltd to allot NCDs aggregating Rs. 465 crores

Newgen extends support to 2,800 children through Shikshaantra Plus program in Govt. Primary School in Harkesh Nagar, Okhla, New Delhi

Federal Bank partners with Pine Labs to enable debit card EMIs

ADOR Fontech Ltd allots 1,75,00,000 bonus equity shares

Infosys Finacle and R3 Conclude Global Trial of Blockchain Based Trade Finance

TCS BaNCS™ Launches Real-time Payments Solution in Multiple Markets to Fuel lnnovation and Enable New Business Models

Thomas Cook India reiterates that there is no impact due to Thomas Cook PLC collapse in the UK

KPR Group brings its organic innerwear collection to Hyderabad

BHEL commissions five units of Kaleshwaram Lift Irrigation Scheme Package 8 (7x139 MW) in Telangana

Prism Johnson Ltd board to consider Q2, H1 results on Nov 5, 2019

Canara Bank to sell its 30% stake in Commonwealth Trust India Ltd

Bajaj Holdings & Investment Ltd board to consider Q2, H1 results on Oct 23, 2019

Cella Space Ltd board to consider availing loan of Rs. 20.80 crore

Punjab & Sind Bank reports Borrowal Fraud of exposure in Era Infra Engineering Limited

Alembic Pharmaceuticals Limited announces completion of USFDA Inspection at Aleor Dermaceuticals Limited

G M Breweries Ltd board to approve Q2, H1 results on Oct 10, 2019

AP Cargo reinforces digital transformation with the implementation of Ramco Logistics Software

2019 the Year of Awards for Intellect GTB (iGTB) Clients: Exclusive Sponsor of the Eighth Annual Transaction Banking Awards Ceremony

Impact of corporate tax announcement on PNB Housing Finance

Indoco successfully completes UK-MHRA inspection at Goa Plant II

Cadila Healthcare Ltd's API facility at Ankleshwar gets EIR from USFDA

IOB raises Rs. 500 cr through Basel III Tier II bonds issue

Intellect Expands Senior Leadership with the Appointment of Vikram Sud as iGTB's Strategic Advisor

Varun Beverages Ltd sees minimal impact on GST increase for Caffeinated Drinks

L&T Construction commences execution of one of India's Largest Communication Network for T-Fibre

U.S. FDA completes inspection of Lupin's Tarapur facility

Petronet LNG inks MOU with Tellurian Inc.

Cipla Ltd receives EIR from USFDA for API facility at Virgonagar

Spirit of Wipro Run Brings Together Participants from 110 Cities Across 34 Nations

Cigniti Technologies Ltd bags 'Corporate Leader of the Year' award at I-ACE awards

Thyrocare Technologies Ltd updates on stake sale in Nueclear Healthcare Ltd

Thomas Cook India, a separate entity and Thomas Cook UK has no stake in India Company

Shri P Jayarama Bhat elected as the Chairman of the governing board of SIBSTC, Bengaluru

Bricwork revises credit rating of Edelweiss Financial Services' NCDs

Capital India Finance Ltd acquires stae in Rapipay Fintech Holding Pvt Ltd

Ravindra Energy Ltd bags contract

Bank of Maharashtra and Paisalo Digital Limited sign Co-Origination of Loan Agreement

Shilpa Medicare Ltd gets shareholders nod for final dividend

Fredun Pharmaceuticals Ltd receives award from Saraswat Co-Operative Bank Ltd

Jump Networks Ltd inks agreement to become the principal sponsor of The Forca Goa Foundation

Sundaram-Clayton Ltd board to approve quarterly results on Oct 18, 2019

Filatex India Ltd updates on expansion project

Karnataka Bank wins ET BUSINESS EXCELLENCE AWARD 2019







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019